Editor’s note

Rather than living in denial and shooting the messenger (Eban in this case), pharma companies have to own up to their mistakes,…

While both governments continue the dialogue, there are various groups working to find a middle path

Will we be safeguarding our national health priorities and standards if we toe the USTR’s line or get a better rank on the GIPC IP…

Even if top management walks the talk, are these concepts filtering down to all employees, especially those at manufacturing…

Besides concerns on data privacy, aren’t such digital initiatives vulnerable to conflict of interests, and merely another…

With women heading Nigeria's NAFDAC, FDA Ghana and FDA Ivory Coast, India could also have a woman DCGI in the not so very distant…

Withdrawal of the GSP scheme could hit the industry quite hard

Pharma companies are likely to spend higher on R&D but without the high returns

A quid pro quo, of an easing drug price control, in exchange for increased investments in manufacturing, backward integration…

Pfizer's loss will be the gain of numerous pharma companies and CROs as they look to hire from this talent pool The new year…